Functionally, ILC2s from PB-MM largely expressed GZMB and exerted cytolytic activity toward MM cells via DNAM-1, while in BM, engagement of TIGIT resulted in ILC2 cell death, thereby suggesting TIGIT as a therapeutic target to restore ILC2 antitumor activity. This evidence concerns the gene GZMB and Miyoshi myopathy.